TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06515990: A Study of DM005 in Patients With Advanced Solid Tumors

Sponsor: Doma Biopharmaceutical（Suzhou）Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 208 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06515990 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06515990 Rescue Dossier →